NASDAQ (usa) arrow 6715.56 -12.11 -0.18%
FTSE 100 (london) arrow 7487.96 -5.12 -0.07%
DAX (german) arrow 13465.51 235.94 1.78%
NIKKEI 225 (japan) arrow 22420.08 408.47 1.86%
Hang - Seng (hong kong) arrow 28594.06 348.52 1.23%
NIFTY - 50 (india) arrow 10188.95 -56.30 -0.55%
Straits Times (singapore) arrow 3391.61 17.53 0.52%
KOSPI (korea) arrow 2556.47 33.04 1.31%
All Ordinaries (australia) arrow 6005.30 28.90 0.48%
BOVESPA (brazil) arrow 74092.76 -215.73 -0.29%

Ampio Pharmaceuticals, Inc. (NASDAQ: AMPE)

 

AMPE Share Price

Open 1.26 Change Price %
High 1.28 1 Day -0.16 -13.11
Low 1.05 1 Week 0.00 0.00
Close 1.06 1 Month -0.02 -1.85
Volume 2171454 1 Year 0.33 45.21
52 Week High 1.34
52 Week Low 0.38
 
AMPE Technical Analysis
5
As on 31st Oct 2017 AMPE Share Price closed @ 1.06 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 0.74 & Strong Buy for SHORT-TERM with Stoploss of 0.71 we also expect STOCK to react on Following IMPORTANT LEVELS.
 
 
NASDAQ USA Most Active Stocks
YHOO 52.58 0.00%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
MU 44.31 6.39%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
INTC 45.49 2.52%
 
NASDAQ USA Top Gainers Stocks
LOCM 0.09 50.00%
SCHS 0.04 33.33%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
HLIT 3.70 25.42%
OTT 2.39 25.13%
QNST 8.90 20.76%
VRTA 4.00 19.40%
SNSS 2.56 19.07%
GCFB 0.44 18.92%
 
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
GMETP 0.15 -76.92%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%
 
 
AMPE
Daily Charts
AMPE
Intraday Charts
AMPE
Free Analysis
Premium
Service
 
AMPE Important Levels Intraday
SUPPORT0.00
SUPPORT0.00
RESISTANCE1.27
RESISTANCE1.19
SUPPORT0.93
SUPPORT0.85
SUPPORT0.00
SUPPORT0.00
 
AMPE Target for Month October
4th UP TARGET2.47
3rd UP TARGET2.02
2nd UP TARGET1.74
1st UP TARGET1.46
1st DOWN TARGET0.66
2nd DOWN TARGET0.38
3rd DOWN TARGET0.1
4th DOWN TARGET-0.35
 
AMPE Weekly Target
4th UP TARGET0.00
3rd UP TARGET0.00
2nd UP TARGET0.00
1st UP TARGET0.00
1st DOWN TARGET0.00
2nd DOWN TARGET0.00
3rd DOWN TARGET0.00
4th DOWN TARGET0.00
 
AMPE Target for Year 2018
4th UP TARGET0
3rd UP TARGET0
2nd UP TARGET0
1st UP TARGET0
1st DOWN TARGET0
2nd DOWN TARGET0
3rd DOWN TARGET0
4th DOWN TARGET0
 
 
AMPE Other Details
Segment EQ
Market Capital 132124608.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.ampiopharma.com
 
AMPE Address
AMPE
5445 DTC Parkway
Suite 925
Greenwood Village, CO 80111
United States
Phone: 720-437-6500
Fax: 720-437-6501
 
AMPE Latest News
 
Your Comments and Response on Ampio Pharmaceuticals, Inc.
 
AMPE Business Profile
Ampio Pharmaceuticals, Inc. (Ampio), incorporated on March 29, 1996, is a development-stage biopharmaceutical company focused on the development of therapies to treat prevalent inflammatory conditions for which there are limited treatment options. The Company is primarily focused on providing medicines to improve the health and quality of life of patients with minimal side effects. Ampio is engaged in developing pharmaceutical drugs and diagnostic products to identify, treat and prevent a range of human diseases, including metabolic disorders, eye disease, kidney disease, and acute and chronic inflammation diseases. In February 2013, it announced the incorporation and initiation of operations of Luoxis Diagnostics. In December 2013, Ampio Pharmaceuticals, Inc. announced that it had spun off its sexual dysfunction business into Vyrix Pharmaceuticals, Inc. Ampion is a non-steroidal anti-inflammatory biologic that has the potential to be used in a range of inflammatory conditions and autoimmune diseases. The active ingredient is aspartyl-alanyl diketopiperazine, referred to as DA-DKP, which is derived from two amino acids from human albumin and appears to have a significant role in the homeostasis of inflammation. Optina is a drug based on a low dose of the weak androgen, low-molecular-weight, very lipophilic steroid danazol. The Company’s in vitro data suggest that danazol has a biphasic effect on endothelial cells, which means at low doses, danazol decreases vascular leakage, while at higher concentrations an increase in vascular permeability is observed. This biphasic effect was supported by the efficacy of danazol in vivo at various BMIs.
 
© 2005-2018 BazaarTrend.com All rights reserved.

Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service